Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
AbbVie Inc banner

AbbVie Inc
SWB:4AB

Watchlist Manager
AbbVie Inc Logo
AbbVie Inc
SWB:4AB
Watchlist
Price: 233.2 EUR 0.3% Market Closed
Market Cap: €273.6B
Write Note Create Alert Ask AI

Wall St Price Targets

4AB Price Forecast
Based on 32 analysts

+6% Upside
from €233.2 today

4AB Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for 4AB yet.

AbbVie Inc Competitors:
Price Targets

Revenue
Forecast

10% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
10% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 6%.

What are analyst estimates?

Gross Profit
Forecast

9% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
9% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 8%.

What are analyst estimates?

Operating Income
Forecast

10% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
10% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 8 years is 11%.

What are analyst estimates?

Pre-Tax Income
Forecast

1% / Year
Past Growth
81% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss
1% / Year
Past Growth
81% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 1%. The projected CAGR for the next 3 years is 81%.

What are analyst estimates?

Net Income
Forecast

-2% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-52%
Average Miss
-2% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-52%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been -2%. The projected CAGR for the next 8 years is 33%.

What are analyst estimates?

Continue 4AB Research

Summary
4AB intrinsic value, competitors valuation, and company profile.
DCF Valuation
4AB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
4AB stock valuation using valuation multiples.
Wall St Estimates
4AB price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
4AB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other AbbVie Inc listings:
NYSE • USD
ABBV
 XETRA • EUR
4AB
 F • EUR
4AB
 BMV • MXN
ABBV
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 4AB's stock price target?
Price Target
247.57 EUR

According to Wall Street analysts, the average 1-year price target for 4AB is 247.57 EUR with a low forecast of 171.29 EUR and a high forecast of 296.42 EUR.

What is the Revenue forecast for AbbVie Inc?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 6%.

What is the Gross Profit forecast for AbbVie Inc?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 8%.

What is the Operating Income forecast for AbbVie Inc?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 8 years is 11%.

What is the Pre-Tax Income forecast for AbbVie Inc?
Projected CAGR
81%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 1%. The projected CAGR for the next 3 years is 81%.

What is the Net Income forecast for AbbVie Inc?
Projected CAGR
33%

Over the last 13 years, the compound annual growth rate for Net Income has been -2%. The projected CAGR for the next 8 years is 33%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.